Uncategorized

Stock Earnings Analysis: Growblox Sciences Inc (GBLX), Earth Science Tech Inc (ETST), Green Cures & Botanical Distribution Inc (GRCU)

Growblox Sciences Inc (OTCMKTS:GBLX) showing jumped of 7.45% and closed at $0.360, after gaining total volume of 440,466.00 shares. Its earnings per share (EPS) is -$0.14 and its beta value stands at -0.34 points and has total market capitalization of $37.78 million and a total of 110.90 million outstanding shares.

Growblox Sciences Inc (GBLX) on February 9, 2017 announced publication of an article and interview discussing GB Sciences Inc.’s (GBLX) holistic approach to cannabis biopharmaceutical development, its commitment to laboratory best practices and certifications, as well as the company’s recent patent filings. CFN Media talks to CSO Dr. Andrea Small-Howard about all of the above in an exclusive video interview.

The cannabis plant is incredibly complex with over 400 chemical entities, including major compounds like tetrahydrocannabinol (THC) and cannabidiol (CBD) that have opposing effects. While the plant has been cultivated for at least 6,000 years, its pharmacological properties have only been analyzed since the end of the nineteenth century. Many breakthroughs didn’t occur until after 2000 when the human endocannabinoid system became more understood. Most companies involved in the cannabis industry are focused on only two of these compounds — THC and CBD — and their effects on a limited number of cannabinoid receptors.

GB Sciences is taking a different approach by embracing the complexity of both the cannabis plant and the endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between dozens of cannabinoids, terpenes and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using both high-throughput screening of accepted cellular models of human diseases and complex statistical and computer models designed to predict outcomes.

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -5.03% and closed at $1.70, with the total traded volume of 23,019.00 shares. During last trade its minimum price was $1.67 and it gained its highest price of $1.79 and has a total of 40.91 million outstanding shares.

On March 27, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries – Earth Science Pharmaceutical Inc. and Cannabis Therapeutics inc. – are proud to announce the projected timeline for the delivery of its MSN-2 medical device; the negotiation of a strategic partnership with Connexions Commerciales Internationales ct, Inc.; and the beginning of negotiations with partners in Africa and Japan.

The MSN-2 medicaldevicewasannounced in November 2016, (https://globenewswire.com/news-release/2016/11/21/891699/0/en/ETST-Announces-60-Patient-Clinical-Prelaunch-Study-for-its-MSN-2-Medical-Device-for-the-Diagnosis-of-Chlamydia-Gonorrhea-ETST-Elects-Dr-Michel-Aubé-as-New-CEO-CSO-and-Nickolas-Tabr.html). The above mentioned medical device can be used by women to extract a cell sample from herself, which then is shipped to a proprietary lab for analysis of sexually transmitted infections. Our device is proven to sample for chlamydia and is currently undergoing testing to certify the device for gonorrhea sampling.

ETST will inaugurate the manufacturing facility for the MSN-2 medical device within Q2 2017, and the initial product release for detecting Chlamydia only may begin as soon as Q3 2017. The MSN-2 will be marketed only overseas during the beginning. The FDA and Health Canada approvals required to market a Class II medical device in Canada and the USA require the factory to be ISO-13485 accredited, which will take more time, estimating within 12 to 18 months.

Green Cures & Botanical Distribution Inc (OTCMKTS:GRCU) decreased -8.54% closed at $0.0150 and traded with total volume of 1.48 million shares, while the average trading remained 1.74 million shares. During last trade its minimum price was $0.01 and it gained the highest price of $0.02. Its market capitalization was $5.36 million.

Green Cures & Botanical Distribution Inc (GRCU) on March 30, 2017 announced that the company has formed a joint venture with Kushtown USA LLC for the US market.

Kushtown is a California based leading edibles company that specializes in cannabis infused medicated water and sodas. Kushtown has been one of the leaders in medical cannabis infused beverages and edible products in California, with products to over 200 medical cannabis dispensaries. Kushtown offers 20 different varieties of medicated soda. Sodas/drinks come in varieties of carbonated and non-carbonated beverages. Flavors like cherry cola, lemonade, fruit punch, and lemon lime are infused with a proprietary THC tincture. Kushtown management plans to leverage the established Kushtown brand name in California and aims to expand the Kushtown brand across the US.

According to Bloomberg.com, edibles comprise approximately half of the legal US cannabis industry. “It’s probably the most exciting segment of the cannabis industry,” says Christian Hageseth, Founder and Chairman of American Cannabis Partners. BusinessInsider.com reports that the North American cannabis market posted $6.7 billion in revenue in 2016, up 30% from the year before. Bloomberg.com estimates that the legal cannabis industry in the US may grow to $50 billion in the next decade, expanding to more than eight times its current size.

Kushtown Management stated, “We are very excited about our joint venture with Green Cures. We have innovative products in the medical cannabis industry that demonstrate that we are a proven market leader as we have created our own footprint in this growing and ever changing industry. Kushtown Sodas are a perfect addition to an already outstanding specialty product line-up.” Green Cures stated, “The Kushtown joint venture will aid in increasing profitable revenue growth in addition to sustaining a long term healthy investment as we work together and continue to increase our specialty product lines.”

 

 

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *